Korean J Thorac Cardiovasc Surg.  2014 Aug;47(4):378-383.

Expression of the Brother of the Regulator of Imprinted Sites Gene in the Sputum of Patients with Lung Cancer

• Lee HY
• Kim JI
• Cho SH
• Ko TY
• Kim HS
• Park SD
• Cho SR
• Chang HK
• Hwang GJ
• Jung SB

Abstract

BACKGROUND
Brother of the regulator of imprinted sites (BORIS) is a putative new oncogene that is classified as a cancer germline gene; however, its role in the development of cancer is unclear. This study investigated the expression of BORIS in lung cancer and its clinical implications.
METHODS
The expression of BORIS messenger ribonucleic acid (mRNA) in the sputum of 100 patients with lung cancer (50 with squamous cell carcinoma, 36 with adenocarcinoma, and 14 with small-cell carcinoma) was evaluated by reverse transcription polymerase chain reaction.
RESULTS
The overall expression rate of BORIS in patients with lung cancer was 36.0%: 19 of 50 squamous cell carcinomas (38.0%), 13 of 36 adenocarcinomas (36.1%), and 4 of 14 (28.6%) small-cell carcinomas. There was no significant difference in the BORIS expression according to age, gender, or histologic type. However, the mRNA expression of BORIS was significantly related to the pathologic cancer stage (p=0.004) and lymph node metastasis (p=0.001). The expression of the melanoma antigen gene family A1-6 was not associated with the expression of BORIS.
CONCLUSION
Our results suggest that the expression of BORIS might be a negative prognostic factor in lung cancers and implicate BORIS as a molecular target for immunotherapy.

Keyword

Lung neoplasms; Brother of the regulator of imprinted sites; Reverse transcription; Polymerase chain reaction

MeSH Terms

Adenocarcinoma
Carcinoma, Squamous Cell
Humans
Immunotherapy
Lung Neoplasms*
Lymph Nodes
Melanoma
Neoplasm Metastasis
Oncogenes
Polymerase Chain Reaction
Reverse Transcription
RNA
RNA, Messenger
Siblings*
Sputum*
RNA
RNA, Messenger